WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
NEW YORK, Feb. 16, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. (“Cardiovascular Systems”) (NASDAQ:CSII) between September 12, 2011 and January 21, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cardiovascular-systems.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cardiovascular-systems.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
